Myeloma and Second Primary Cancers
Authors:
- Ola LandgrenOLOla Landgren
- Anish ThomasATAnish Thomas
- Sham MailankodySMSham Mailankody
- 8 December 2011
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 365 (23) , 2241-2242
Abstract
In December 2010, results from three randomized, phase 3 trials of treatments for multiple myeloma showed an excess of hematologic cancers among patients with multiple myeloma who received lenalidomide maintenance therapy (see Table 1 in the Supplementary Appendix, available with the full text of this letter at NEJM.org). Researchers have been aware of second cancers after multiple myeloma — particularly acute myeloid leukemia and myelodysplastic syndromes — for more than four decades (Table 1 in the Supplementary Appendix). In 1979, Bergsagel et al. (see the Supplementary Appendix) found an increased risk of all forms of acute leukemia among 364 patients with multiple myeloma treated with low-dose melphalan (Table 1 in the Supplementary Appendix). Studies conducted after the introduction of high-dose melphalan followed by autologous stem-cell transplantation suggested that conventional chemotherapy before autologous stem-cell transplantation is a more likely contributing factor to myelodysplastic syndromes and acute myeloid leukemia than pretransplantation myeloablative therapy (Table 1 in the Supplementary Appendix).Keywords
This publication has 5 references indexed in Scilit:
- Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS)Blood, 2011
- Polymorphism of the erythropoietin gene promotor and the development of myelodysplastic syndromes subsequent to multiple myelomaLeukemia, 2011
- Patterns of Improved Survival in Patients With Multiple Myeloma in the Twenty-First Century: A Population-Based StudyJournal of Clinical Oncology, 2010
- Mechanisms of therapy-related carcinogenesisNature Reviews Cancer, 2005
- Risk of Second Malignancy After Hodgkin’s Disease in a Collaborative British Cohort: The Relation to Age at TreatmentJournal of Clinical Oncology, 2000